Literature DB >> 21463130

Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia.

Renata Canalle1, Vanessa S Silveira, Carlos Alberto Scrideli, Rosane G P Queiroz, Luiz Fernando Lopes, Luiz Gonzaga Tone.   

Abstract

The aim of this study was to evaluate the frequency of polymorphisms in the TYMS, XRCC1, and ERCC2 DNA repair genes in pediatric patients with acute lymphoblastic leukemia using polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (RFLP) approaches. The study was conducted in 206 patients and 364 controls from a Brazilian population. No significant differences were observed among the analyzed groups regarding XRCC1 codon 399 and codon 194 and ERCC2 codon 751 and codon 312 polymorphisms. The TYMS 3R variant allele was significantly associated with a reduced risk of childhood ALL, represented by the sum of heterozygous and polymorphic homozygous genotypes (odds ratio 0.60; 95% confidence interval 0.37-0.99). The results suggest that polymorphism in TYMS may play a protective role against the development of childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463130     DOI: 10.3109/10428194.2011.559672

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

1.  CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome.

Authors:  Vanessa S Silveira; Renata Canalle; Carlos Alberto Scrideli; Rosane G P Queiroz; Luiz Fernando Lopes; Luiz Gonzaga Tone
Journal:  Mol Cell Biochem       Date:  2012-01-04       Impact factor: 3.396

2.  DNA repair gene XRCC1 polymorphisms and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis.

Authors:  Juan Du; Cong Lu; Guohui Cui; Yan Chen; Jing He
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

3.  XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls.

Authors:  Yi Huang; Denghai Xie; Nana Tang; Jishi Wang; Xiaoqing Zeng; Peng Zhao; Ling He
Journal:  Tumour Biol       Date:  2013-08-30

4.  Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies.

Authors:  Yan-Zhong Feng; Yi-Ling Liu; Xiao-Feng He; Wu Wei; Xu-Liang Shen; Dao-Lin Xie
Journal:  Tumour Biol       Date:  2014-07-27

5.  Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies.

Authors:  Lizhi Tang; Tianyuan Xiong; Qingyi Jia; Qing He; Xiang Tong; Yuanling Peng; Jiani Shen; Jiqiao Yang; Yonggang Zhang
Journal:  Tumour Biol       Date:  2014-01-12

Review 6.  Current evidence for an inherited genetic basis of childhood acute lymphoblastic leukemia.

Authors:  Kevin Y Urayama; Anand P Chokkalingam; Atsushi Manabe; Shuki Mizutani
Journal:  Int J Hematol       Date:  2012-12-13       Impact factor: 2.490

7.  The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies.

Authors:  Liang Du; Yuqi Liu; Pei Xue; Chenxi Song; Jiani Shen; Qing He; Yuanling Peng; Xiang Tong; Lizhi Tang; Yonggang Zhang
Journal:  Tumour Biol       Date:  2015-01-27

8.  Thymidylate synthase polymorphisms and risk of conotruncal heart defects.

Authors:  Huiping Zhu; Wei Yang; Nathan Shaw; Spencer Perloff; Suzan L Carmichael; Richard H Finnell; Gary M Shaw; Edward J Lammer
Journal:  Am J Med Genet A       Date:  2012-08-07       Impact factor: 2.802

9.  A case-parent triad assessment of folate metabolic genes and the risk of childhood acute lymphoblastic leukemia.

Authors:  Philip J Lupo; Darryl Nousome; Kala Y Kamdar; M Fatih Okcu; Michael E Scheurer
Journal:  Cancer Causes Control       Date:  2012-09-01       Impact factor: 2.506

10.  The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.

Authors:  Moh'd Khushman; Girijesh Kumar Patel; Anu Singh Maharjan; Gwendolyn A McMillin; Cindy Nelson; Peter Hosein; Ajay P Singh
Journal:  Pharmacogenomics J       Date:  2021-02-19       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.